Alembic Pharmaceuticals Limited · NSE:APLLTD
Alembic Pharmaceuticals — Q4 FY20 Earnings Presentation
15 slides from Alembic Pharmaceuticals's earnings presentation, March 2020
Slide 1: Alembic Pharmaceuticals Limited Investor presentation – March 2020
Alembic Pharmaceuticals Limited Investor presentation – March 2020 BSE & NSE: APLLTD
Slide 2: Milestones
Milestones 1907 Established by Amin family 2006 FDA approves API facility 2007 Acquired Dabur’s Indian Cardiology, GI and Gynaecology brands 2008 FDA approves Formulation facility 2010 Pharmaceuticals business demerged from Alembic – APL listed 2012 Formed a JV, Rhizen, for NCE research Launched fir
Slide 3: Financial Highlights
Financial Highlights INR Bn Particulars Q4 FY20 Q4 FY19 Growth YTD FY20 YTD FY19 Growth Net Sales 12.07 9.27 30% 46.06 39.35 17% EBIDTA Pre R&D 5.13 2.84 81% 18.15 13.38 36% Margin % 42% 31% 39% 34% R&D 1.85 1.20 55% 6.45 4.98 29% R&D % 15% 13% 14% 13% EBIDTA Post R&D 3.39 1.74 95% 12.13 8.75 39% Ma
Slide 4: Business snapshot – Q4FY20
Business snapshot – Q4FY20 Formulations Generics Branded API Total US Ex-US India Revenue Q4FY20 (INR Bn) 5.77 1.32 3.42 1.55 12.07 Vet API 13% 13% 2% Q4FY20 Revenue Acute Generics 48% 11% 59% Contribution Branded 28% 11% Speciality 15% Growth Q4FY20 -33% 84% 63% 13% 30% over Q4FY19 Growth Q4FY20 -1
Slide 5: Business snapshot – YTD FY20
Business snapshot – YTD FY20 Formulations Generics Branded API Total US Ex-US India Revenue YTD FY20 (INR Bn) 19.76 4.97 14.25 7.08 46.06 API Vet 15% 15% 3% Generics YTD FY20 Revenue 43% Acute 54% Contribution 11% Branded 31% 11% Speciality 17% Growth YTD FY20 -8% 53% 1% 3% 17% over YTD FY19 • Well-
Slide 6: US Generic
US Generic INR Bn Revenue – Q4 FY20 INR Bn Revenue – Last 5 Years CAGR - 13% 19.76 5.77 12.28 12.88 9.19 9.20 3.13 Q4FY19 Q4FY20 FY16 FY17 FY18 FY19 FY20 Approved ANDAs Milestones & Updates Derma 8 Ophthalmic ➢ 69 products launched through the US front end (5 launched in 11 Q4FY20, 22 Launched in YT
Slide 7: Ex-US Generics
Ex-US Generics Revenue : Q4 FY20 INR Bn Revenue – Last 5 Years INR Bn CAGR - 21% 1.32 0.81 4.94 4.97 Q4FY19 Q4FY20 3.20 ➢ Presence in following markets 2.86 - Europe, Canada, Australia, Brazil and South Africa 2.34 ➢ The business will focus on new launches across key markets ➢ Plant successfully aud
Slide 8: API
API Revenue : Q4 FY20 INR Bn Revenue – Last 5 Years INR Bn 2.30 CAGR - 8% 1.55 7.71 7.08 6.40 6.51 Q4FY19 Q4FY20 5.25 ➢ Sales across geographies as preferred supplier ➢ Investing in plants to create additional capacities ➢ FDA Compliant plants ➢ State of the art R&D center and Process development la
Slide 9: R&D Significant investments in building capabilities
R&D Significant 10.0 investments in building capabilities INR Bn ANDA – Accelerated filings & approvals 37* 8.0 Filing 13.7% 14.0% 13.1% 12.7% 29 30 Approval 6.0 25 10.1% R&D Spend 20 19 18* * 11 Filings & 4.0 7 Approvals 6.5 R&D % of 10 were 5.0 sales 2.0 4.3 4.1 8 contributed by 3.2 5 acquisition
Slide 10: State of the art facilities and infrastructure
State of the art facilities and infrastructure Audit/Filing Location Dosage Form status International Generics F1 – Panelav General Oral Solids Mar’20* Oncology Oral Solids Jun’19* F2 – Panelav Oncology Injectables H2FY21# F2 - Panelav F3 - Karkhadi General Injectables F3 – Karkhadi Ophthalmic Jan’2
Slide 11: Branded Business
Branded Business Revenue – Q4 FY20 INR Bn Revenue – Last 5 Years CAGR - 5% INR Bn 13.8 14.3 3.42 12.5 12.7 3.03 11.8 0.29 Vet 0.31 1.32 Acute 1.07 Speciality 1.65 1.81 Q4FY19 Q4FY20 FY16 FY17 FY18 FY19 FY20 Marketing organization Key achievements ➢ 5000 + Marketing team ➢ 3 Brands in top 300 ➢ 17 Ma
Slide 12: Therapy-wise Performance Q4 FY20
Therapy-wise Performance Q4 FY20 Q4 FY20 Q4 FY19 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Cardiology 15 2.0 11 18 11 2.1 16 10 Anti Diabetic 13 1.5
Slide 13: Therapy-wise Performance YTD Mar’20
Therapy-wise Performance YTD Mar’20 YTD Mar’20 YTD Mar’19 Therapy Market Alembic Alembic Therapy Market Alembic Alembic Therapy (%) Growth Share % Growth % Growth % Growth Share Growth % Growth % % (ORG) (ORG) (ORG) (PRIM) % (ORG) % (ORG) (ORG) (PRIM) Anti Diabetic 13 1.5 3 3 14 1.7 15 11 Cardiology
Slide 14: Financials : Generating consistent returns
Financials : Generating consistent returns Revenue EBIDTA Net Profit INR Bn 46.06 INR Bn 12.13 INR Bn 8.29 20.53 4.03 2.83 11.38 1.17 0.39 FY10 FY15 FY20 FY10 FY15 FY20 FY10 FY15 FY20 10 Years CAGR - 15% 10 Years CAGR - 26% 10 Years CAGR - 36% EBIDTA margin % Capex ROCE % 32 INR Bn 6.97 52 26 6.04 6
Slide 15: Thank you
Thank you Safe Harbour Agreement: Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and resu
Alembic Pharmaceuticals — Q4 FY20 Earnings Presentation on 6ix